BCL2 and cancer: To take one step further to determine the mode of action of the tested compounds, a molecular docking study was employed to determine the binding modes against series of proteins such as CDK2, BCL2, Jak2, P53 binding site in MDM2, and DHFR that are implicated significantly in cancer disease (Figures S1–S5).